Arbaclofen Placarbil in GERD: A Randomized, Double-Blind, Placebo-Controlled Study

Abstract

AP was not superior to placebo in reducing the number of weekly heartburn events over 4 weeks in the primary analysis of the entire study population. Exploratory subgroup analyses suggest that response to PPI treatment before the study was associated with a response to AP treatment.